Subclinical hypothyroidism and cardiovascular risk: Recommendations for treatment

Cardiology in Review

Volumn 19, Issue 6, 2011, Pages 291-299

  Weiss, Irene A ^a   Bloomgarden, Noah ^b   Frishman, William H ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

cardiovascular complications; subclinical hypothyroidism; thyroid replacement; thyroid stimulating hormone

Indexed keywords

LIOTHYRONINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROID HORMONE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE;

ADRENERGIC SYSTEM; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; GROUPS BY AGE; HEART FUNCTION; HEART HEMODYNAMICS; HORMONAL THERAPY; HORMONE TRANSPORT; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; LIPID ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; SEX DIFFERENCE; SUBCLINICAL HYPOTHYROIDISM; THYROID HORMONE SYNTHESIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

CARDIOVASCULAR DISEASES; HUMANS; HYPOTHYROIDISM; RISK FACTORS; THYROID GLAND; THYROID HORMONES;

EID: 80054046945     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318227df87     Document Type: Review

References (97)

1. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76-131. (Pubitemid 351252748)
2. Larsen PR, Davies TF, Schlumberger ML, et al. Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In: Kronenberg HM, Melmed S, Polonsky KS, et al, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier; 2008:299-332.
3. Pol CJ, Muller A, Simonides WS. Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: An adaptative response or part of the problem? Heart Fail Rev. 2010;15:133-142.
4. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990;88:626-630. (Pubitemid 20192278)
5. Morkin E. Regulation of myosin heavy chain genes in the heart. Circulation. 1993;87:1451-1460. (Pubitemid 23133087)
6. 2+ transport and myocardial relaxation. Circ Res. 1994;75:245-251.
7. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725-1735. (Pubitemid 47537847)
8. Kamitani T, Ikeda U, Muto S, et al. Regulation of Na, K-ATPase gene expression by thyroid hormone in rat cardiocytes. Circ Res. 1992;71:1457-1464.
9. Dozin B, Magnuson MA, Nikodem VM. Thyroid hormone regulation of malic enzyme synthesis. Dual tissue-specific control. J Biol Chem. 1986;261: 10290-10292. (Pubitemid 17221965)
10. Ladenson PW, Block KD, Seidman JG. Modulation of atrial natriuretic factor by thyroid hormone: Messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology. 1988;123:652-657.
11. Kim D, Smith TW, Marsh JD. Effect of thyroid hormone on slow calcium channel function in cultured chick ventricular cells. J Clin Invest. 1987;80: 88-94. (Pubitemid 17097520)
12. Stiles GL, Lefkowitz RJ. Thyroid hormone modulation of agonist-betaadrenergic receptor interactions in the rat heart. Life Sci. 1981;28:2529-2536. (Pubitemid 11094761)
13. Walker JD, Crawford FA Jr, Mukherjee R, et al. Direct effects of acute administration of 3, 5, 3' triiodo-L-thyronine on myocyte function. Ann Thorac Surg. 1994;58:851-856. (Pubitemid 24319645)
14. Klein I. Thyroid hormone and the cardiovascular system. Am J Med. 1990; 88:631-637. (Pubitemid 20192279)
15. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509. (Pubitemid 32164903)
16. Klein I. Thyroid hormone and blood pressure regulation. In: Laragh JH, Brenner BM, Kaplan NM, eds. Endocrine Mechanisms of Hypertension. New York, NY: Raven Press; 1989:1661.
17. Dillmann WH. Cardiac function in thyroid disease: Clinical features and management considerations. Ann Thorac Surg. 1993;56:S9 -S14; discussion S14-S15.
18. Amidi M, Leon DF, DeGroot WJ, et al. Effect of the thyroid state on myocardial contractility and ventricular ejection rate in man. Circulation. 1968;38:229-239.
19. Liggett SB, Shah SD, Cryer PE. Increased fat and skeletal muscle betaadrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis. J Clin Invest. 1989;83:803-809. (Pubitemid 19080609)
20. Walker JD, Crawford FA Jr, Mukherjee R, et al. The direct effects of 3,5,3'-triiodo-L-thyronine (T3) on myocyte contractile processes. Insights into mechanisms of action. J Thorac Cardiovasc Surg. 1995;110:1369 -1379; discussion 1379-1380.
21. Ririe DG, Butterworth JF IV, Royster RL, et al. Triiodothyronine increases contractility independent of beta-adrenergic receptors or stimulation of cyclic-3',5'-adenosine monophosphate. Anesthesiology. 1995;82: 1004-1012.
22. Ojamaa K, Kenessey A, Klein I. Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology. 2000;141:2139-2144. (Pubitemid 32274367)
23. Pachucki J, Burmeister LA, Larsen PR. Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res. 1999;85:498-503. (Pubitemid 29431950)
24. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499. (Pubitemid 34158210)
25. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-534. (Pubitemid 30112276)
26. Helfand M; U.S. Preventive Services Task Force. Screening for subclinical thyroid dysfunction in nonpregnant adults: A summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2004;140: 128-141.
27. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 1995;43:55-68.
28. Szabolcs I, Podoba J, Feldkamp J, et al. Comparative screening for thyroid disorders in old age in areas of iodine deficiency, long-term iodine prophylaxis and abundant iodine intake. Clin Endocrinol (Oxf). 1997;47:87-92. (Pubitemid 27313993)
29. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: Prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab. 2002;87:3221-3226. (Pubitemid 34816369)
30. Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: An analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab. 2004;89:4890-4897. (Pubitemid 39391424)
31. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010;52: 151-156.
32. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88:2438-2444. (Pubitemid 36724408)
33. Schwandt P, Weisweiler P. The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia. Atherosclerosis. 1980;35:301-306. (Pubitemid 10174128)
34. Lopez D, Abisambra Socarras JF, Bedi M, et al. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta. 2007; 1771:1216-1225. (Pubitemid 47404963)
35. Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA. 2005;102: 10297-10302. (Pubitemid 41024974)
36. Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: The Tromso study. J Intern Med. 2006;260:53-61. (Pubitemid 43894070)
37. Danese MD, Ladenson PW, Meinert CL, et al. Clinical review 115: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature. J Clin Endocrinol Metab. 2000;85: 2993-3001.
38. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: Response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab. 2002;87:1533-1538. (Pubitemid 34615234)
39. Villar HC, Saconato H, Valente O, et al. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev. 2007: CD003419.
40. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with 'high-normal' TSH levels: Should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol. 1998;138:141-145. (Pubitemid 28131089)
41. Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: Cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003;166:379-386. (Pubitemid 36071697)
42. Ozcan O, Cakir E, Yaman H, et al. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2005;63:203-206. (Pubitemid 41097990)
43. Kvetny J, Heldgaard PE, Bladbjerg EM, et al. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf). 2004;61:232-238. (Pubitemid 39093119)
44. Tuzcu A, Bahceci M, Gokalp D, et al. Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J. 2005;52:89-94. (Pubitemid 40410323)
45. Hueston WJ, King DE, Geesey ME. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin Endocrinol (Oxf). 2005;63: 582-587. (Pubitemid 41626755)
46. Lee WY, Suh JY, Rhee EJ, et al. Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lpa levels according to thyroid function status. Arch Med Res. 2004;35:540-545.
47. Muller B, Tsakiris DA, Roth CB, et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest. 2001;31:131-137. (Pubitemid 32199906)
48. Canturk Z, Cetinarslan B, Tarkun I, et al. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid. 2003;13:971-977. (Pubitemid 37351881)
49. Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol. 2005;152:355-361. (Pubitemid 40439487)
50. Guldiken S, Demir M, Turgut B, et al. Global fibrinolytic capacity in patients with subclinical hypothyroidism. Endocr J. 2005;52:363-367. (Pubitemid 41003528)
51. Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88:3731-3737. (Pubitemid 37034521)
52. Shakoor SK, Aldibbiat A, Ingoe LE, et al. Endothelial progenitor cells in subclinical hypothyroidism: The effect of thyroid hormone replacement therapy. J Clin Endocrinol Metab. 2010;95:319-322.
53. Razvi S, Ingoe L, Keeka G, et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: Randomized, crossover trial. J Clin Endocrinol Metab. 2007;92:1715-1723. (Pubitemid 46997177)
54. Gokce N, Keaney JF Jr, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: A prospective study. Circulation. 2002;105:1567-1572. (Pubitemid 34297634)
55. Volzke H, Robinson DM, Spielhagen T, et al. Are serum thyrotropin levels within the reference range associated with endothelial function? Eur Heart J. 2009;30:217-224.
56. Xiang GD, He YS, Zhao LS, et al. Impairment of endothelium-dependent arterial dilation in Hashimoto's thyroiditis patients with euthyroidism. Clin Endocrinol (Oxf). 2006;64:698-702.
57. Fernandez-Real JM, Lopez-Bermejo A, Castro A, et al. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects. J Clin Endocrinol Metab. 2006;91:3337-3343. (Pubitemid 44402101)
58. Nagasaki T, Inaba M, Kumeda Y, et al. Decrease of arterial stiffness at common carotid artery in hypothyroid patients by normalization of thyroid function. Biomed Pharmacother. 2005;59:8-14. (Pubitemid 40312273)
59. Dagre AG, Lekakis JP, Papaioannou TG, et al. Arterial stiffness is increased in subjects with hypothyroidism. Int J Cardiol. 2005;103:1-6. (Pubitemid 41074596)
60. Obuobie K, Smith J, Evans LM, et al. Increased central arterial stiffness in hypothyroidism. J Clin Endocrinol Metab. 2002;87:4662-4666. (Pubitemid 35247058)
61. Owen PJ, Rajiv C, Vinereanu D, et al. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab. 2006;91:2126-2132. (Pubitemid 43854994)
62. Monzani F, Caraccio N, Kozakowa M, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: A double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2004;89:2099-2106. (Pubitemid 38619837)
63. Brent GA, Larsen PR, Davies TF, et al. Hypothyroidism and thyroiditis. In: Kronenberg HM, Melmed S, Polonsky KS, et al, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier; 2008:377-409.
64. Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: A double blind, placebocontrolled study. J Clin Endocrinol Metab. 2001;86:1110-1115. (Pubitemid 32322990)
65. Biondi B, Fazio S, Palmieri EA, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1999; 84:2064-2067. (Pubitemid 30647034)
66. Aghini-Lombardi F, Di Bello V, Talini E, et al. Early textural and functional alterations of left ventricular myocardium in mild hypothyroidism. Eur J Endocrinol. 2006;155:3-9. (Pubitemid 44103368)
67. Ripoli A, Pingitore A, Favilli B, et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol. 2005;45:439-445. (Pubitemid 40186797)
68. Yazici M, Gorgulu S, Sertbas Y, et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: Index of myocardial performance in the evaluation of left ventricular function. Int J Cardiol.2004;95:135-143. (Pubitemid 38757618)
69. Brenta G, Mutti LA, Schnitman M, et al. Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. Am J Cardiol. 2003;91:1327-1330. (Pubitemid 36593477)
70. Akcakoyun M, Kaya H, Kargin R, et al. Abnormal left ventricular longitudinal functional reserve assessed by exercise pulsed wave tissue Doppler imaging in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 2009;94:2979-2983.
71. Iqbal A, Schirmer H, Lunde P, et al. Thyroid stimulating hormone and left ventricular function. J Clin Endocrinol Metab. 2007;92:3504-3510. (Pubitemid 47435327)
72. Asvold BO, Bjoro T, Nilsen TI, et al. Thyrotropin levels and risk of fatal coronary heart disease: The HUNT study. Arch Intern Med. 2008;168:855-860. (Pubitemid 351620087)
73. Vanderpump MP, Tunbridge WM, French JM, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid. 1996;6:155-160. (Pubitemid 26279405)
74. Razvi S, Weaver JU, Vanderpump MP, et al. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: Reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab.2010;95:1734-1740.
75. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med. 2000;132:270-278. (Pubitemid 30106257)
76. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:2467-2472. (Pubitemid 41720007)
77. Iervasi G, Molinaro S, Landi P, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007;167:1526-1532. (Pubitemid 47124183)
78. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033-1041.
79. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122:385-393.
80. Rodondi N, Bauer DC, Cappola AR, et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health Study. J Am Coll Cardiol. 2008;52:1152-1159.
81. Razvi S, Shakoor A, Vanderpump M, et al. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: A metaanalysis. J Clin Endocrinol Metab. 2008;93:2998-3007.
82. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148:832-845. (Pubitemid 351786932)
83. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304:1365-1374.
84. Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab. 2009;94:1342-1345.
85. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252. (Pubitemid 24333188)
86. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet. 2001;358:861-865. (Pubitemid 32900566)
87. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis. Eur J Endocrinol.1994;130:350-356. (Pubitemid 24135720)
88. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J Clin Endocrinol Metab.1996;81:4278-4289. (Pubitemid 26412030)
89. Bauer DC, Ettinger B, Nevitt MC, et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561-568. (Pubitemid 32245317)
90. Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186-193.
91. Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med. 2002;162:338-343. (Pubitemid 34127412)
92. Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591-2599. (Pubitemid 39577515)
93. van den Beld AW, Visser TJ, Feelders RA, et al. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90:6403-6409. (Pubitemid 41759292)
94. Atzmon G, Barzilai N, Hollowell JG, et al. Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab. 2009;94:1251-1254.
95. Meyerovitch J, Rotman-Pikielny P, Sherf M, et al. Serum thyrotropin measurements in the community: Five-year follow-up in a large network of primary care physicians. Arch Intern Med. 2007;167:1533-1538. (Pubitemid 47124184)
96. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238. (Pubitemid 38082818)
97. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract. 2004;10:497-501.